Macular degeneration and other retinal diseases drugs

 Macular degeneration and other retinal diseases drugs

Visiongain has published a global macular degeneration (AMD) and other retinal diseases drugs market report 2021-2031.Forecasts By Indication (diabetic macular edema, diabetic retinopathy, retinal vein occlusion, others). By Type (Wet AMD, Dry AMD, Geographic Atrophy) By Product (Lucentis, Eylea, Avastin, Visudyne, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) PLUS, Profiles of Leading global macular degeneration (AMD) and other retinal diseases drugs companies and regional and leading national market Analysis. PLUS COVID-19 Recovery Scenarios

Visiongain lead analyst says: ‘Global macular degeneration drugs market was valued at US$ 19.18billion in 2020 and is projected to reach at a market value of US$ 40.16billion by 2031. Rising investment in drug R&D by pharmaceutical and biopharmaceutical companies, increasing prevalence of retinal diseases, mounting demand for biologics & biosimilars, and…

Read full article…www.globenewswire.com